Journal of Biological Chemistry · 2005 · 152 citations · 32 references
Life SciencesMolecular BiologyOncologyMolecular Cell BiologyProtein-protein InteractionsStructural BiologyLigand BindingMacromolecular StructureProtein StructureStructural MotifsHelix - Turn - Helix MotifsHelix-loop-helix MotifHelix-turn-helix MotifsMultidimensional Nmr SpectroscopyThree-dimensional Nmr SpectroscopyTumor Suppressor P53Turn MotifTwo-dimensional Nmr Spectroscopy
Mdm2 is a cellular antagonist of p53 that keeps a balanced cellular level of p53. The two proteins are linked by a negative regulatory feedback loop and physically bind to each other via a putative helix formed by residues 18-26 of p53 transactivation domain (TAD) and its binding pocket located within the N-terminal 100-residue domain of mdm2 (Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. (1996) Science 274, 948-953). In a previous report we demonstrated that p53 TAD in the mdm2-freee state is mostly unstructured but contains two nascent turns in addition to a "preformed" helix that is the same as the putative helix mediating p53-mdm2 binding. Here, using heteronuclear multidimensional NMR methods, we show that the two nascent turn motifs in p53 TAD, turn I (residues 40-45) and turn II (residues 49-54), are also capable of binding to mdm2. In particular, the turn II motif has a higher mdm2 binding affinity ( approximately 20 mum) than the turn I and targets the same site in mdm2 as the helix. Upon mdm2 binding this motif becomes a well defined full helix turn whose hydrophobic face formed by the side chains of Ile-50, Trp-53, and Phe-54 inserts deeply into the helix binding pocket. Our results suggest that p53-mdm2 binding is subtler than previously thought and involves global contacts such as multiple "non-contiguous" minimally structured motifs instead of being localized to one small helix mini-domain in p53 TAD.
32
Bert Vogelstein, David P. Lane, Arnold J. Levine · Nature · 2000 · 6.6K citations
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Yunje Cho, Svetlana S. Gorina, Philip D. Jeffrey et al. · Science · 1994 · 2.5K citations
DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2
Sheau-Yann Shieh, Masako Ikeda, Yoichi Taya et al. · Cell · 1997 · 2.1K citations · Full text